What requirements do Biotech companies need to consider during clinical development to ensure that patients will gain access to their innovative therapies? How must Biotech companies adapt in order to be successful in an increasingly cost-conscious world?
FACILITATED BY
MEL WALKER | Managing Director | BioPharma Futures
Faced with ongoing change what have we learnt that will serve us well as we lead in 2021 and beyond…
• Why will leading change continue to be important in 2021 and beyond?
• How can we reset and reenergize?
• What are the key success factors in leading change?
FACILITATED BY
KATHRYN SIMPSON | Business Consultant | Kathryn Simpson Consulting
PANELLISTS INCLUDE
JOHN POTTAGE | Former Senior Vice President, Chief Scientific and Medical Officer | ViiV Healthcare TOBY REID | Chief Executive Officer | BioCity Group
COVID-19 vaccines have shown the public just how fast we can develop, assess and approve medicines. How can we accelerate these timelines outside of a pandemic?
FACILITATED BY
IAN MUIR | Chief Executive Officer | Porton Biopharma
Brexit and the imminent funding gap has led to companies looking to locate elsewhere. We hear from countries/regions trying to attract Life Science companies.
FACILITATED BY
KATH MACKAY | Managing Director | Bruntwood SciTech – Alderley Park
£1m – £5m is the new funding valley of death. How do you effectively position your business for Series A funds, and how do you select investors that are right for you?
With increased public funding in coronavirus detection and vaccines, and restrictions on funding from the EU, will there be a major gap in life science funding?
FACILITATED BY
RICHARD HEBDON | Interim Deputy Director – Health & Life Sciences | Innovate UK
How, where, when and if to grow are decisions critical to the success of all biotech focused companies – spanning products to services. How do you plan, implement and adapt your growth strategy?
Value creation through growth is an imperative for all companies. What strategies work best in the biotech world?
Strategies invariably evolve over time. We will hear from companies that have pivoted from service to product – and vice versa. Is this by design or by necessity?
Self-proclaimed serial entrepreneurs are abundant. Where are the serial scalers? Do they exist? Are they hidden? Are they tied up in longer-term projects?
What tools and techniques exist to support the development of growth strategies? What works? Are they transferable?
